Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159239 | 0.93 | L3MBTL1 (0.47) | L3MBTL1ATMGPR119KMT2AKLK5 | |
| SCHEMBL4360263 | 0.85 | CETP (0.40) | L3MBTL1ATMGPR119CETPKMT2A | |
| SCHEMBL2358236 | 0.83 | GPR119 (0.39) | L3MBTL1GPR119KMT2AMAPK1KLK5 | |
| SCHEMBL2358238 | 0.83 | GPR119 (0.39) | L3MBTL1GPR119KMT2AMAPK1KLK5 | |
| SCHEMBL476216 | 0.82 | ABCB1 (0.40) | GPR119MAPK1STSYAP1GAA | |
| SCHEMBL476217 | 0.82 | ABCB1 (0.40) | GPR119MAPK1STSYAP1GAA | |
| SCHEMBL3859795 | 0.81 | KLK7 (0.47) | L3MBTL1GPR119KMT2AMAPK1KLK5 | |
| SCHEMBL3855675 | 0.81 | KLK7 (0.47) | L3MBTL1GPR119KMT2AMAPK1KLK5 | |
| SCHEMBL2570206 | 0.81 | KLK7 (0.47) | L3MBTL1GPR119KMT2AMAPK1KLK5 | |
| SCHEMBL3855672 | 0.81 | KLK7 (0.47) | L3MBTL1GPR119KMT2AMAPK1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | L3MBTL1 4137/4885ATM 4476/4885GPR119 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.